This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Possible Marker for Aggressive Disease

Nada L. Wood, PhD; Edward N. Kitces, MD, PhD; W. Kenneth Blaylock, MD

Arch Dermatol. 1990;126(7):907-913.

Abstract
• Peripheral blood mononuclear cells from 24 patients with mycosis fungoides were used to generate lymphokine activated killer (LAK) cells in vitro by culturing with recombinant interleukin 2. Patients with stage la mycosis fungoides were capable of generating normal levels of LAK cell activity, while patients with more active disease (stages IB to IV) had depressed LAK activity. The ability of these patients' cells to respond in a proliferation assay to various mitogens was similar to that of controls, with the exception of patients in the terminal phase of their illness. Patients with active disease who were unable to generate LAK activity were capable of responding in a proliferation assay to interleukin 2. The results of this study suggest that depressed LAK cell activity in patients with mycosis fungoides may serve as an indicator of a more aggressive disease state.

(Arch Dermatol. 1990;126:907-913)

Author Affiliations
From the Department of Dermatology, Medical College of Virginia-Virginia Commonwealth University, Richmond. Dr Kitces is now with the McGuire Clinic, Richmond.

Footnotes
Accepted for publication February 1, 1990.

Reprint requests to Department of Dermatology, Medical College of Virginia, PO Box 164, MCV Station, Richmond, VA 23298 (Dr Wood).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Yano et al.
Clin. Cancer Res. 2007;13:6494-6500.
ABSTRACT | FULL TEXT  

Impaired CD40L signaling is a cause of defective IL-12 and TNF-{alpha} production in Sezary syndrome: circumvention by hexameric soluble CD40L
French et al.
Blood 2005;105:219-225.
ABSTRACT | FULL TEXT  

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15
Wysocka et al.
Blood 2004;104:4142-4149.
ABSTRACT | FULL TEXT  

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Lundin et al.
Blood 2003;101:4267-4272.
ABSTRACT | FULL TEXT  

Fas Ligand Expression by Neoplastic T Lymphocytes Mediates Elimination of CD8+ Cytotoxic T Lymphocytes in Mycosis Fungoides: A Potential Mechanism of Tumor Immune Escape?
Ni et al.
Clin. Cancer Res. 2001;7:2682-2692.
ABSTRACT | FULL TEXT  

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses
Rook et al.
Blood 1999;94:902-908.
ABSTRACT | FULL TEXT  

Immunoregulatory Events in the Skin of Patients With Cutaneous T-Cell Lymphoma
Hansen
Arch Dermatol 1996;132:554-561.
ABSTRACT  

Increased Serum Concentration of the Soluble Interleukin-2 Receptor in Cutaneous T-Cell Lymphoma: Clinical and Prognostic Implications
Wasik et al.
Arch Dermatol 1996;132:42-47.
ABSTRACT  

Peripheral Blood Mononuclear Cells in Patients With Nonleukemic Cutaneous T-Cell Lymphoma: Reduced Proliferation and Preferential Secretion of a T Helper-2--Like Cytokine Pattern on Stimulation
Dummer et al.
Arch Dermatol 1993;129:433-436.
ABSTRACT